Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRASG12C-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies [0.03%]
一项关于评价IBI351（福瑞替尼）单药治疗KRASG12C抑制剂初治的中国携带KRAS G12C突变的转移性结直肠癌患者的疗效和安全性：来自两个I期研究的汇总分析
Ying Yuan,Yanhong Deng,Yongdong Jin et al.
Ying Yuan et al.
IBI351 (also known as fulzerasib or GFH925), an irreversible covalent inhibitor of KRASG12C, has demonstrated promising anti-tumour activity in patients with solid tumours. In this study, data were pooled from the phase I part of two clinic...
Pseudohypoxic stabilization of HIF1α via cyclophilin D suppression promotes melanoma metastasis [0.03%]
环孢素D抑制假缺氧诱导的HIF1α稳定促进黑色素瘤转移
Hye-Kyung Park,Sung Hu,So Yeon Kim et al.
Hye-Kyung Park et al.
Stabilization of hypoxia-inducible factor 1 alpha (HIF1α), which plays a pivotal role in regulating cellular responses to insufficient oxygen, is implicated in cancer progression, particularly epithelial-mesenchymal transition and metastat...
Molecular mechanisms of unique therapeutic potential of CUDC-907 for MEF2D fusion-driven BCP-ALL [0.03%]
靶向MEF2D融合阳性B细胞急性淋巴细胞白血病的候选药物CUDC-907的分子机制研究
Qing Xue,Ming Zhang,Yixiao Mo et al.
Qing Xue et al.
MEF2D fusions are found in a special subtype of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with poor prognosis. In this study, we conducted high-throughput drug screenings using cell line and ex vivo cell model harboring, respe...
Current landscape of innovative drug development and regulatory support in China [0.03%]
中国创新药研发及监管支持现状分析
Ruirong Tan,Hua Hua,Siyuan Zhou et al.
Ruirong Tan et al.
The global pharmaceutical landscape remains dynamic and competitive, shaped by advancements in first-in-class therapies and breakthrough technologies. The United States has maintained its leadership in first-in-class therapies and breakthro...
Exploratory phase II trial of an anti-PD-1 antibody camrelizumab combined with a VEGFR-2 inhibitor apatinib and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis [0.03%]
卡瑞利珠单抗联合阿帕替尼和化疗新辅助治疗三阴性乳腺癌的探索性Ⅱ期研究（NeoPanDa03）：疗效、安全性及生物标志物分析
Xiaoxiao Liu,Chunying Zhuang,Lei Liu et al.
Xiaoxiao Liu et al.
Chemotherapy serves as the primary therapeutic approach for triple-negative breast cancer (TNBC), yet its efficacy remains unsatisfactory. This study was a single-arm, open-label, single-center clinical trial (NCT05447702) involving patient...
Aberrant Notch-signaling promotes tumor angiogenesis in esophageal squamous-cell carcinoma [0.03%]
诺特信号异常可促进食道鳞状细胞癌的肿瘤血管生成
Cainan Li,Pujie Wu,Xiaoting Xie et al.
Cainan Li et al.
Esophageal squamous-cell carcinoma (ESCC) is one of the most common gastrointestinal cancers in China, characterized by high malignancy and poor prognosis. Nowadays, the therapeutic options for this cancer are very limited. Notch-signaling ...
Differential expression pattern of CC chemokine receptor 7 guides precision treatment of hepatocellular carcinoma [0.03%]
C趋化因子受体7的差异表达模式引导肝细胞癌的精准治疗
Jie Qin,Qianyi Gong,Cheng Zhou et al.
Jie Qin et al.
The treatment of hepatocellular carcinoma (HCC) faces challenges of low response rates to targeted drugs and immune checkpoint inhibitors, which are influenced by complicated microenvironment of HCC. In this study, the complex tumor microen...
Phosphoglycerate dehydrogenase stabilizes protein kinase C delta type mRNA to promote hepatocellular carcinoma progression [0.03%]
磷酸甘油酸脱氢酶稳定蛋白激酶C delta型mRNA以促进肝细胞癌进展
Bin Cheng,Pai Peng,Shi Chen et al.
Bin Cheng et al.
Metabolic reprogramming not only reshapes cellular bioenergetics but also profoundly influences RNA metabolism through metabolite signaling and the RNA-binding activities of metabolic enzymes. Emerging evidence highlights that certain metab...
Correction: Clinical investigation on nebulized human umbilical cord MSC-derived extracellular vesicles for pulmonary fibrosis treatment [0.03%]
关于人脐带间充质干细胞来源外泌体治疗肺纤维化临床研究的更正公告
Meng Li,Huaping Huang,Xiaofei Wei et al.
Meng Li et al.
Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance [0.03%]
表观遗传调控因子在克服癌症治疗耐药方面颇具潜力
Jiawei Song,Ping Yang,Canting Chen et al.
Jiawei Song et al.
Cancer remains one of the leading health threats globally, with therapeutic resistance being a long-standing challenge across chemotherapy, radiotherapy, targeted therapy, and immunotherapy. In recent years, the association between epigenet...